DOVATO is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.[1]
DOVATO vs. BIC/FTC/TAF Why start with DOVATO? Your DOVATO patients
Proven non‑inferior efficacy vs. BIC/FTC/TAF in naïve to treatment participants[2]
At Week 48, 89% of participants receiving DOVATO achieved viral suppression (HIV-1 RNA <50 copies/mL), demonstrating non-inferior efficacy vs. BIC/FTC/TAF (92%), including in participants with baseline viral load ≥100,000 copies/mL (85% vs. 89%).[2]
Proportion of participants with HIV-1 RNA <50 copies/mL at Week 48
(Primary endpoint analysis: FDA Snapshot algorithm; -10% non-inferiority margin)[2]
Adapted from Ghosn J et al. 2026.[2]
0 cases of treatment emergent resistance with DOVATO (n=0/254) vs. 0 (n=0/255) with BIC/FTC/TAF at Week 48*,[2]
Participants were allowed to rapidly start treatment, even when no resistance testing results were available at baseline[2]
The safety profile of DOVATO was comparable to BIC/FTC/TAF through Week 48, with no new safety signals identified:
Presenting with a high viral load and unknown baseline resistance
Presenting with a very high viral load in a test-and-treat setting
Presenting with low CD4+ T-cell count and additional health concerns
* Among the 14 participants meeting CVW criteria, resistance data were obtained for 6 participants (DOVATO, n=2; BIC/FTC/TAF, n=4) and no treatment-emergent resistance to INSTIs or NRTIs was identified. For the remaining 8 participants (DOVATO, n=5; BIC/FTC/TAF, n=3) , resistance testing failed due to the VL of samples being below the assay cutoff.[2]
† Treatment-related AE leading to discontinuation with BIC/FTC/TAF included weight increase (n=1) and alopecia (n=1).[2]
‡ Resistance-associated mutations (RAMs) at screening were reviewed once results became available (approximately Week 4). Participants with major resistance-associated mutations to INSTIs, 3TC, FTC, or TAF were required to discontinue study treatment.[2]
§ Participants with immunity to HBV, including those with isolated hepatitis B core antibody positivity without detectable HBV DNA were not excluded.[2]
AE, adverse event; ART, antiretroviral therapy; BIC, bictegravir; BL, baseline; CI, confidence interval; CVW, confirmed virologic withdrawal; DDI, drug-drug interaction; DHHS, Department of Health and Human Services; EACS, European AIDS Clinical Society; FDA, United States Food and Drug Administration; FTC, emtricitabine; HBV, Hepatitis B Virus; IAS, International Antiviral Society; INSTI, integrase strand transfer inhibitor; ITT, intention-to-treat; NRTI, nucleoside reverse transcriptase inhibitor; RCT, randomised controlled trial; TAF, tenofovir alafenamide; VL, viral load; WHO, World Health Organisation.
References:
- DOVATO (dolutegravir/lamivudine) Summary Product of Characteristics (SmPC)
- Ghosn J et al. Slides presented at AIDS. 26-31 July 2026. Rio de Janeiro, Brazil, OAB0106LB.
- Cahn P et al. AIDS 2022; 36(1): 39–48.
- Executive summary — UNAIDS. 2025 Global AIDS Update — AIDS, Crisis and the Power to Transform. Available at: Executive summary. Available at: https://www.unaids.org/en/resources/documents/2025/2025-global-aids-update-summary. Accessed October 2026.
- Fraysse J et al. Infect Dis Ther. 2025; 14(2): 357–383.
- Lazarus J et al. HIV Med. 2023; 24: 8–19. (Suppl Appendix 2).
- Figueroa M et al. Clin Infect Dis 2026; 82(1): 122–131.
- Figueroa M et al. Slides presented at HIV Glasgow. 10–13 November 2024. Glasgow, UK. 024.
- Cordova E et al. Lancet HIV 2025; 12(2): 1–10.
- Rolle C et al. Open Forum Infect Dis 2023; 10(3): ofad101.
- Department of Health and Human Services (DHSS). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. September 2026.
- Gandhi R et al. JAMA 2025; 333(7): 609–628.
- ̌European AIDS Clinical Society (EACS) Guidelines. Version 13.0. October 2025.
- World Health Organisation. Recommendations on first- and second-line antiretroviral regimens. July 2019.
- Trickey A et al. Lancet HIV 2023; 10(5): e295–e307.
PM-GB-DLL-WCNT-250004 V2 | October 2026
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.